Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib.
J Oncol Pharm Pract
; 28(8): 1906-1909, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-1714589
ABSTRACT
INTRODUCTION:
The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection. CASE REPORTS A 58-year-old man and a 65-year-old woman were diagnosed as ALK ( + ) NSCL CA. Both patients received tyrosine kinase inhibitors (TKI) for lung cancer when diagnosed with COVID-19. No adverse effects were observed with the concurrent use of Favipiravir, an antiviral drug currently used for COVID-19 and TKI. MANAGEMENT ANDOUTCOME:
Considering the pharmacokinetic effects of favipiravir and the ALK inhibitor TKI's used on our cases (Brigatinib-Lorlatinib), the concurrent use of these drugs was safe and prevented the delay in the primary treatment of the malignancy of our patients.DISCUSSION:
To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
COVID-19 Drug Treatment
/
Lung Neoplasms
Type of study:
Case report
/
Prognostic study
/
Qualitative research
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Oncol Pharm Pract
Journal subject:
Pharmacy
Year:
2022
Document Type:
Article
Affiliation country:
10781552221083321
Similar
MEDLINE
...
LILACS
LIS